Pulmonary function and survival one year after dupilumab treatment of acute moderate to severe COVID-19: A follow up study from a Phase IIa trial.
Jennifer HendrickJennie Z MaHeather M HaugheyRachael ColemanCarol A GilchristAlexandra KadlJeffrey M SturekPatrick E H JacksonMary K YoungJudith E AllenWilliam A PetriPublished in: medRxiv : the preprint server for health sciences (2023)
We observed evidence of reduced long-term morbidity and mortality from COVID-19 with dupilumab treatment during acute hospitalization when added to standard of care regimens.